Global pharmaceutical firms are ramping up competition in South Africa’s emerging obesity treatment market, with Danish giant Novo Nordisk cutting prices on its weight-loss drug Wegovy to gain an edge over U.S.-based rival Eli Lilly.
Novo Nordisk announced on Wednesday that the lowest injectable dose of Wegovy will fall from 3,090 rand (US$181.70) to 1,873 rand, while the highest dose is reduced by 27 percent to 3,746 rand. This marks the company’s second price cut since entering South Africa, Africa’s most industrialised economy, in August 2025.
The move is aimed at undercutting Eli Lilly, whose obesity drug equivalents start at around 3,600 rand, and capturing a larger share of a market analysts say is under-served. Novo Nordisk is also evaluating further reductions to its mid-level dose and exploring the introduction of an oral version of Wegovy to broaden accessibility.
South Africa presents a high-growth opportunity for weight-loss treatments. According to the World Health Organization, more than half of South African adults, and over two-thirds of women, are overweight or obese, among the highest rates in sub-Saharan Africa. Despite this, treatment penetration remains extremely low, with fewer than 1 percent of the roughly 20 million affected individuals receiving medication, according to Sara Norcross, managing director of Novo Nordisk South Africa.
The intensifying rivalry reflects a global trend in the obesity pharmaceutical market. In Europe and the Americas, Novo Nordisk and Eli Lilly are competing aggressively, with Goldman Sachs Research projecting the global market for obesity treatments could reach $100 billion annually by 2030.
The South African market’s potential is further strengthened by regulatory developments. Internal documents reported by Reuters indicate the World Health Organization is preparing to formally endorse weight-loss drugs for adult obesity treatment for the first time in May 2025, signaling a shift from a historical focus on prevention and lifestyle interventions to pharmaceutical solutions.
Novo Nordisk first entered the South African market with its flagship type 2 diabetes drug, Mounjaro, in partnership with Aspen in December 2024, later securing approval for weight-loss indications in October 2025. The company’s aggressive pricing strategy in South Africa mirrors global efforts to expand its footprint in fast-growing obesity markets while remaining competitive against Eli Lilly.
Industry analysts say South Africa’s obesity treatment market is attractive because of both scale and unmet demand. High prevalence rates, combined with low treatment coverage, create a significant growth opportunity for pharmaceutical companies willing to invest in distribution, education, and price accessibility.
More Read
“South Africa is one of the most promising markets for obesity medications in Africa,” said an independent healthcare analyst based in Johannesburg. “Competition between these multinational firms will likely accelerate adoption, reduce prices, and increase access for patients who previously had few options.”
The market could see further expansion as health insurers and private healthcare providers adjust coverage to accommodate pharmaceutical weight-loss treatments, while ongoing awareness campaigns raise patient demand.
With obesity linked to increased risk of cardiovascular disease, diabetes, and other chronic conditions, health authorities are under pressure to provide treatment options. This creates a dual incentive for drugmakers: a rapidly expanding consumer base and the potential to partner with public and private healthcare systems to scale treatment programs.
As Novo Nordisk and Eli Lilly battle for market share, South Africa is set to become a testing ground for pricing strategies, product innovation, and patient adoption trends in sub-Saharan Africa, potentially shaping the regional trajectory of obesity treatment in the years ahead.
